Summary

for people ages 18-55 (full criteria)
at San Francisco, California and other locations
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with progressive Multiple Sclerosis (PMS).

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Keywords

Multiple Sclerosis (MS)Progressive multiple sclerosisSclerosisMultiple SclerosiselezanumabElezanumab Dose 1Elezanumab Dose 2

Eligibility

You can join if…

Open to people ages 18-55

  • Subject has diagnosis of primary-progressive multiple sclerosis (PPMS) or non-relapsing secondary-progressive multiple sclerosis (SPMS) and no relapses for at least 24 months
  • Subject has evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test

You CAN'T join if...

  • Treatment with any of the following within the 6 months prior to Screening: natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; intravenous immunoglobulin (IVIg); any interferon product; and intravenous (IV), oral, or intrathecal corticosteroids for the purposes of disease modification
  • Treatment with the following within 1 year prior to Screening: cyclophosphamide or alemtuzumab

Locations

  • UCSF School of Medicine - Neurology /ID# 203194not yet accepting patients
    San FranciscoCalifornia94143-0003United States
  • Jordan Research and Education Development Institute (REDI) /ID# 202448not yet accepting patients
    BerkeleyCalifornia94705-2002United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03737812
Phase
Phase 2
Study Type
Interventional
Last Updated